Pfizer (PFE) Competitors $23.06 -0.46 (-1.96%) Closing price 03:59 PM EasternExtended Trading$23.07 +0.01 (+0.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PFE vs. JNJ, ABBV, MRK, BMY, ZTS, RPRX, CORT, JAZZ, PRGO, and SUPNShould you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry. Pfizer vs. Johnson & Johnson AbbVie Merck & Co., Inc. Bristol-Myers Squibb Zoetis Royalty Pharma Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Is JNJ or PFE a better dividend stock? Johnson & Johnson pays an annual dividend of $5.20 per share and has a dividend yield of 3.4%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.3%. Johnson & Johnson pays out 57.8% of its earnings in the form of a dividend. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has raised its dividend for 64 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Does the media prefer JNJ or PFE? In the previous week, Pfizer had 6 more articles in the media than Johnson & Johnson. MarketBeat recorded 89 mentions for Pfizer and 83 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 1.13 beat Pfizer's score of 0.83 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 57 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 56 Very Positive mention(s) 10 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 7 Very Negative mention(s) Positive Which has more risk & volatility, JNJ or PFE? Johnson & Johnson has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Does the MarketBeat Community prefer JNJ or PFE? Pfizer received 384 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 68.87% of users gave Pfizer an outperform vote while only 64.70% of users gave Johnson & Johnson an outperform vote. CompanyUnderperformOutperformJohnson & JohnsonOutperform Votes112764.70% Underperform Votes61535.30% PfizerOutperform Votes151168.87% Underperform Votes68331.13% Do insiders and institutionals have more ownership in JNJ or PFE? 69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings & valuation, JNJ or PFE? Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJohnson & Johnson$89.33B4.15$14.07B$8.9917.12Pfizer$62.46B2.13$8.03B$1.3816.99 Is JNJ or PFE more profitable? Johnson & Johnson has a net margin of 18.20% compared to Pfizer's net margin of 12.62%. Johnson & Johnson's return on equity of 34.24% beat Pfizer's return on equity.Company Net Margins Return on Equity Return on Assets Johnson & Johnson18.20% 34.24% 13.63% Pfizer 12.62%19.47%8.09% Do analysts rate JNJ or PFE? Johnson & Johnson currently has a consensus target price of $170.88, indicating a potential upside of 11.03%. Pfizer has a consensus target price of $29.17, indicating a potential upside of 24.40%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Johnson & Johnson 0 Sell rating(s) 11 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.55Pfizer 1 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 3 Strong Buy rating(s) 2.53 SummaryJohnson & Johnson beats Pfizer on 15 of the 22 factors compared between the two stocks. Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PFE vs. The Competition Export to ExcelMetricPfizerPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$132.78B$6.54B$5.40B$19.57BDividend Yield7.53%2.66%5.22%3.84%P/E Ratio16.569.1826.7134.73Price / Sales2.13256.43395.4435.66Price / Cash6.3865.8538.2517.51Price / Book1.486.536.854.75Net Income$8.03B$144.00M$3.23B$1.02B7 Day Performance6.52%5.01%5.35%-0.01%1 Month Performance6.23%9.58%13.31%11.33%1 Year Performance-17.91%-0.94%17.58%4.69% Pfizer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PFEPfizer4.9955 of 5 stars$23.06-2.0%$29.17+26.5%-17.6%$131.10B$62.46B16.3583,000Trending NewsJNJJohnson & Johnson4.953 of 5 stars$151.97+0.4%$170.88+12.4%+1.5%$365.71B$89.33B22.86152,700Trending NewsABBVAbbVie4.822 of 5 stars$185.14+0.6%$210.95+13.9%+12.2%$326.99B$57.37B77.1350,000Trending NewsMRKMerck & Co., Inc.4.9985 of 5 stars$76.88+1.1%$109.19+42.0%-40.5%$192.86B$63.92B11.4169,000Positive NewsAnalyst DowngradeBMYBristol-Myers Squibb4.6971 of 5 stars$46.87+0.3%$58.00+23.8%+10.3%$95.35B$47.64B-10.6034,300Positive NewsZTSZoetis4.6288 of 5 stars$163.63+0.4%$212.75+30.0%-6.2%$72.85B$9.29B29.9113,800Positive NewsRPRXRoyalty Pharma4.7697 of 5 stars$33.91-0.3%$42.50+25.3%+20.4%$19.53B$2.26B23.3780Positive NewsAnalyst DowngradeCORTCorcept Therapeutics4.5152 of 5 stars$74.50-0.8%$138.25+85.6%+163.9%$7.91B$685.45M59.17300Insider TradeJAZZJazz Pharmaceuticals4.9387 of 5 stars$109.26+0.3%$182.79+67.3%+2.2%$6.74B$4.06B15.403,200Positive NewsPRGOPerrigo4.6425 of 5 stars$27.12+0.3%$33.00+21.7%-7.2%$3.73B$4.34B-23.188,900Positive NewsSUPNSupernus Pharmaceuticals2.808 of 5 stars$33.33-0.3%$36.00+8.0%+15.4%$1.87B$668.00M31.15580Positive News Related Companies and Tools Related Companies Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Corcept Therapeutics Alternatives Jazz Pharmaceuticals Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PFE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PFE Stock Free PFE Stock Alerts